Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Non-current Assets
All assets not expected to be converted to cash within one year.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Non-current Assets · Q4 FY2025 · quarter ended Dec 2025
Total non-current assets remains negative
Q4 FY2025 total non-current assets was $0, compared with $387.44K a year earlier.
Context
- Total non-current assets amounted to 0.0% of total assets at the end of Q4 FY2025, down 2.0 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 387.44K | +523.5% |
| FY2023 | 2023-12-31 | 62.14K | +312.9% |
| FY2022 | 2022-12-31 | 15.05K | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Assets vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 10, against a peer median of +0.3%.
- Total non-current assets amounts to 0.0% of total assets for NNNN, versus a peer median of 40.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $9.41B USD | -10.3% | -4.9% | 71.4% | |
| Mar 2026 | CA$894.19M CAD | +0.3% | -5.7% | 68.1% | |
| Mar 2026 | $725.1M USD | -4.0% | -14.8% | 69.1% | |
| Mar 2026 | $270.58M USD | +820.1% | +146.0% | 53.6% | |
| Feb 2026 | $105.13M USD | -7.1% | -35.1% | 40.3% | |
| Mar 2026 | $38.54M USD | +558.1% | +99.4% | 41.3% | |
| Mar 2026 | $25.69M USD | +153.7% | +86.0% | 18.9% | |
| Mar 2026 | $20.87M USD | +52.7% | +49.5% | 3.9% | |
| Dec 2025 | $15.23M USD | — | — | 4.5% | |
| Mar 2026 | $4.36M USD | -14.7% | -24.2% | 3.4% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | -100.0% | — | 0.0% |
| Peer median (excluding NNNN) | — | +0.3% | -4.9% | 40.8% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.